Founded in 2008 in Denmark, Reapplix has developed a highly innovative treatment for diabetic foot ulcers. Diabetic foot ulcers are a relatively common health condition (with an annual incidence of over one million cases per year in the United States). For the patient, the risk of aggravation is real and can lead to amputation or death.

Reapplix is positioned as a key innovator specifically addressing this unmet need with several major differentiating factors. The effectiveness of its solution, the 3C Patch, has been demonstrated by robust clinical studies and recognized by a publication in the Lancet, the world’s gold standard journal on the subject. In addition, attractive reimbursement conditions have been secured in the United States, paving the way for an ambitious commercial rollout plan for the solution. The team driving Reapplix has extensive commercialization expertise in this market.

Company : Reapplix

Investment type : Growth Equity

Investment date : November 2021

Location : Denmark

Website :

FDA approval
Positive Medicare National coverage Determination
% Odds of healing versus standard of care *

* Adjusted for ulcer area, Lancet Diabetes Endocrinol 2018; 6: 870-878

“Reapplix has transformed the management of hard-to-heal diabetic foot ulcers by enabling patients’ own living cells to heal their wounds. Our commercial scale up will give Medicare patients broad access to a therapy that can spare amputations and save lives.”

Samuel Levy, Founding Partner at Lauxera